Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD8 aptamer-siRNA
- Development stage
- Preclinical
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
CD8 aptamer-siRNA refers to a class of chimeric oligonucleotides (aptamer-siRNA chimeras, or AsiCs) designed for the targeted delivery of small interfering RNA (siRNA) payloads specifically to CD8+ T cells. The aptamer portion of the chimera binds with high affinity to the CD8 cell surface receptor, facilitating receptor-mediated internalization of the conjugate. Once inside the cell, the siRNA payload is processed to silence specific target genes. Different variations of this platform have been developed for distinct therapeutic purposes: silencing RGS1 (regulator of G-protein signaling 1) to enhance CD8+ T cell recruitment and anti-tumor immunity in breast cancer; silencing granulysin (GNLY) to suppress cytotoxic T lymphocyte-mediated cytotoxicity in Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and graft-versus-host disease (GVHD); and silencing mTORC1 to promote memory T cell differentiation.
- Other names
- anti-CD8 aptamer-siRNAanti-CD-8 aptamer-siRNAanti-CD 8 aptamer-siRNACD8 aptamer-siRNA chimeraCD-8 aptamer-siRNA chimeraCD 8 aptamer-siRNA chimeraCD8-AsiCCD-8-AsiCCD 8-AsiC
02
Targets
AMP (Antimicrobial peptide family)
Beyond the preview
Go deeper on CD8 aptamer-siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD8 aptamer-siRNA.